Nasdaq

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...
Yahoo Finance

Immunoglobulin Market Growth Trends Strategies and Forecasts Report 2025-2033 | IVIg Dominates as Subcutaneous Immunoglobulin Gains Momentum In Home Care

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 ...
Seeking Alpha

CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...
The Reporter

Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients

KING OF PRUSSIA, Pa., April 29, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra ...

KORU Medical Systems Inc (KRMD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

KORU Medical Systems Inc (KRMD) reports robust international expansion and increased revenue guidance despite domestic revenue decline and margin pressures.